Verisante Technology, Inc. Announces Exclusive Distribution Agreement with Pacifica Handels AG for Switzerland

Verisante Technology, Inc. Announces Exclusive Distribution Agreement with 
Pacifica Handels AG for Switzerland 
Switzerland Has Third Highest Skin Cancer Rate in the World 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/19/13 -- Verisante
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that the Company has entered into an exclusive
agreement with Pacifica Handels AG to distribute Verisante Aura(TM)
in Switzerland.  
"Pacifica Handels AG is an award-winning distributor of medical
devices in Switzerland," said Thomas Braun, President & CEO of
Verisante. "Pacifica knows the market for dermatological and skin
care devices in Switzerland intimately, and this specialized
knowledge in a country that has the third highest skin cancer rate in
the world will be extremely helpful with market penetration. Pacifica
will distribute Aura(TM) and also support technical training and
servicing in Switzerland." 
Pacifica is based in Baar, Switzerland and distributes innovative
products for the world's leading global manufacturer of medical laser
and IPL(TM) systems for use in aesthetics, dermatology, and other
applications. Aura(TM) is a complementary addition to the Company's
existing product line. 
"There is an epidemic of skin cancer in Switzerland," said Dr. Heiner
Gronewald, Managing Director of Pacifica. "Aura's(TM) impressive
clinical study results show it can quickly and accurately assist in
skin cancer diagnosis, and I am confident this tool will be welcomed
by doctors and clinics across Switzerland." 
The European medical device market is the second largest in the
world, worth over $78 billion and representing 30 per cent of the
world market - second only to the United States. Switzerland has a
population of nearly 8 million people, and 400 dermatologists serving
the country.  
According to the Swiss Federal Health Office, Switzerland has the
third highest skin cancer rate in the world behind Australia and New
Zealand, and has more new melanoma cases per year than any other
country in Europe, with 22 new cases recorded annually for every
100,000 people. Over the last 20 years, cases of malignant melanoma
in Switzerland have doubled and in 30 percent of cases, melanoma
occurs in people before they reach the age of 50. 
Verisante Aura(TM) is indicated for use for the evaluation of skin
lesions that may be clinically suspicious for melanoma, squamous cell
carcinoma and/or basal cell carcinoma when a medical professional
chooses to obtain additional information to rule out one of the above
conditions before making a final decision to biopsy. Aura(TM) is a
non-invasive optical system that uses Raman spectroscopy to
biochemically analyze the skin, providing immediate results. The
device will help to automate the current process of diagnosis,
allowing rapid scanning of the 20 to 40 skin lesions on at-risk
individuals, improving patient outcomes and comfort. 
About Pacifica Handels AG 
Pacifica Handels AG is a privately owned medical device distributor
of innovative solutions for professionals in dermatology, plastic
surgery, urology, ENT, neuro-surgery, and gynaecology, founded in
Switzerland with head office in Baar. 
Pacifica has been serving doctors' offices and hospitals for more
than five years and knows the market very well. The Company works
closely with its clients, offering continuous consulting before and
after sales, training in theory and practice by experienced users and
our qualified training staff, and a workshop platform for inter-user
For more information on Pacifica, visit the Company's website at  
About Verisante Technology, Inc. 
Verisante is a medical device company committed to commercializing
innovative systems for the early detection of cancer. The Verisante
Aura(TM) for skin cancer detection and the Verisante Core(TM) series
for lung, colon and cervical cancer detection utilize a proprietary
cancer detection platform while the operating software and probe
technology are unique to each device. The cancer detection platform
was developed by the BC Cancer Agency and tested and refined at the
Skin Care Centre at Vancouver General Hospital. This exclusive
platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians
immediate results for many of the most common cancers. Aura(TM) has
been approved for sale in Canada, Europe and Australia. The Core(TM)
has not yet been approved for sale.  
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of
What's New Award" for 2011, and awarded a 2013 Prism Award for
Innovation in Photonics. Verisante Core(TM) was named one of the top
10 cancer breakthroughs of 2011 by the Canadian Cancer Society.  
Forward Looking Statements  
This release contains forward-looking statements, including, but not
limited to, statements regarding the future commercialization of
medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks, and
the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. 
The TSX Venture Exchange has neither approved nor disapproved of the
contents of this press release. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release. 
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507 
Press spacebar to pause and continue. Press esc to stop.